Harrison DG, Coffman TM, Wilcox CS. Pathophysiology of hypertension: The Mosaic Theory and Beyond. Circ Res. 2021;128:847–63.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72:e53–90.

CAS  PubMed  Article  Google Scholar 

Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16:14–26.

Article  Google Scholar 

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.

PubMed  Article  Google Scholar 

Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Prim. 2018;4:18014.

PubMed  Article  Google Scholar 

Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Bmj. 2003;326:1427.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Clin Hypertens (Greenwich). 2011;13:146–54.

Article  Google Scholar 

Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl J Med. 2008;359:2417–28.

CAS  PubMed  Article  Google Scholar 

Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173–81.

CAS  PubMed  Article  Google Scholar 

Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr., Whelton PK, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936–46.

CAS  PubMed  Article  Google Scholar 

Wright JT Jr., Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. Jama. 2002;288:2421–31.

CAS  PubMed  Article  Google Scholar 

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349:1857–63.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl J Med. 2001;345:851–60.

CAS  PubMed  Article  Google Scholar 

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl J Med. 2001;345:861–9.

CAS  PubMed  Article  Google Scholar 

Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2021. https://doi.org/10.1111/bph.15747.

Barrera-Chimal J, Jaisser F, Anders HJ. The mineralocorticoid receptor in chronic kidney disease. Br J Pharmacol. 2021. https://doi.org/10.1111/bph.15734.

Barrera-Chimal J, Kolkhof P, Lima-Posada I, Joachim A, Rossignol P, Jaisser F. Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. Expert Opin Investig Drugs. 2021;30:1141–57.

CAS  PubMed  Article  Google Scholar 

Chow CPLJ, Tan XJ, Huang ZH. Pharmacological Profile of Kbp-5074, a novel nonsteroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal diseases. J Drug Res Dev. 2017;3:67–75.

Google Scholar 

Pitt B, Jaisser F, Bakris G. An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension. Expert Opin Investig Drugs. 2021;30:1017–23.

CAS  PubMed  Article  Google Scholar 

Jaisser F, Tan X, Chi S, Liu J, Wang P, Bush M, et al. The non-steroidal mineralocorticoid receptor antagonist KBP-5074 limits Albuminuria and has improved therapeutic index compared with Eplerenone in a Rat Model With mineralocorticoid-induced renal injury. Front Pharm. 2021;12:604928.

CAS  Article  Google Scholar 

Zhang B, Tan X, Ni S. Pharmacokinetics and safety of KBP-5074 in phase 1 single and multiple ascending dose studies. Paper presented at: Poster presented at American Society of Nephrology Kidney Week meeting 2016.

Zhang BCP, Smith WB, Lasseter K, Yang F, Tan X, Pelka P. Safety, tolerability and pharmacokinetics of KBP-5074 in patients with mild-to-moderate chronic kidney disease [Abstract PUB116]. J Am Soc Nephrol. 2016;27:931A.

Google Scholar 

Bakris G, Yang YF, Pitt B. Mineralocorticoid receptor antagonists for Hypertension management in advanced Chronic Kidney Disease: BLOCK-CKD Trial. Hypertension. 2020;76:144–9.

CAS  PubMed  Article  Google Scholar 

Bakris G, Pergola PE, Delgado B, Genov D, Doliashvili T, Vo N, et al. Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study. Hypertension. 2021;78:74–81.

CAS  PubMed  Article  Google Scholar 

Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014;34:333–9.

CAS  PubMed  Article  Google Scholar 

Trensz F, Bortolamiol C, Kramberg M, Wanner D, Hadana H, Rey M, et al. Pharmacological characterization of Aprocitentan, a dual Endothelin receptor antagonist, alone and in combination with blockers of the Renin Angiotensin System, in two models of experimental Hypertension. J Pharm Exp Ther. 2019;368:462–73.

CAS  Article  Google Scholar 

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–5.

CAS  PubMed  Article  Google Scholar 

Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens. 1997;15:57–63.

CAS  PubMed  Article  Google Scholar 

Gueneau de Mussy P, Sidharta PN, Wuerzner G, Maillard MP, Guérard N, Iglarz M, et al. Effects of the dual Endothelin receptor antagonist aprocitentan on body weight and fluid homeostasis in healthy subjects on a high Sodium diet. Clin Pharm Ther. 2021;109:746–53.

CAS  Article  Google Scholar 

Iglarz M, Clozel M. At the heart of tissue: endothelin system and end-organ damage. Clin Sci (Lond). 2010;119:453–63.

CAS  Article  Google Scholar 

Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation. 2004;110:2233–40.

CAS  PubMed  Article  Google Scholar 

Sen S, Chen S, Feng B, Iglarz M, Chakrabarti S. Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist. Life Sci. 2012;91:658–68.

CAS  PubMed  Article  Google Scholar 

McCoy EK, Lisenby KM. Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension. J Cardiovasc Pharm. 2021;77:699–706.

CAS  Article  Google Scholar 

Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension. 2008;52:452–9.

CAS  PubMed  Article  Google Scholar 

Angeli F, Verdecchia P, Reboldi G. Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension. Cardiol Ther. 2021;10:397–406.

PubMed  PubMed Central  Article  Google Scholar 

Angeli F, Reboldi G, Verdecchia P. Interpretation of ambulatory blood pressure profile: a prognostic approach for clinical practice. J Hypertens. 2015;33:454–7.

CAS  PubMed  Article  Google Scholar 

Sidharta PN, Ulč I, Dingemanse J. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment. Clin Drug Investig. 2019;39:1117–23.

CAS  PubMed  Article  Google Scholar 

Verweij P, Danaietash P, Flamion B, Ménard J, Bellet M. Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension. Hypertension. 2020;75:956–65.

CAS  PubMed  Article  Google Scholar 

Kohan DE, Pollock DM. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharm. 2013;76:573–9.

CAS  Google Scholar 

Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21:527–35.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Black HR, Bakris GL, Weber MA, Weiss R, Shahawy ME, Marple R, et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich). 2007;9:760–9.

CAS  Article  Google Scholar 

Burnier M. Update on Endothelin Receptor Antagonists in Hypertension. Curr Hypertens Rep. 2018;20:51.

PubMed  Article  Google Scholar 

Georgi